Skip to main content
Erschienen in: Urolithiasis 3/2017

17.09.2016 | Original Paper

A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass

verfasst von: Pietro Manuel Ferraro, Angelo Minucci, Aniello Primiano, Elisa De Paolis, Jacopo Gervasoni, Silvia Persichilli, Alessandro Naticchia, Ettore Capoluongo, Giovanni Gambaro

Erschienen in: Urolithiasis | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Mutations of the CYP24A1 gene, encoding for the enzyme 25(OH)D-24-hydroxylase, can cause hypercalcemia, hypercalciuria, nephrolithiasis and nephrocalcinosis. We report the case of a 22-year-old male patient with recurrent nephrolithiasis, nephrocalcinosis, hypercalcemia with low parathyroid hormone levels, hypercalciuria and low bone mass. Gene sequencing showed that the patient had compound heterozygous mutations including a novel genotype of the CYP24A1 gene. Genetic CYP24A1 testing and biochemical analyses were offered to other family members; the father was heterozygous for the same novel genotype and was also affected with recurrent nephrolithiasis.
Literatur
1.
Zurück zum Zitat Tebben PJ, Milliner DS, Horst RL et al (2012) Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 97(3):E423–E427CrossRefPubMedPubMedCentral Tebben PJ, Milliner DS, Horst RL et al (2012) Hypercalcemia, hypercalciuria, and elevated calcitriol concentrations with autosomal dominant transmission due to CYP24A1 mutations: effects of ketoconazole therapy. J Clin Endocrinol Metab 97(3):E423–E427CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Schlingmann KP, Kaufmann M, Weber S et al (2011) Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365(5):410–421CrossRefPubMed Schlingmann KP, Kaufmann M, Weber S et al (2011) Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Engl J Med 365(5):410–421CrossRefPubMed
3.
Zurück zum Zitat Streeten EA, Zarbalian K, Damcott CM (2011) CYP24A1 mutations in idiopathic infantile hypercalcemia. N Engl J Med 365(18):1741–1743CrossRefPubMed Streeten EA, Zarbalian K, Damcott CM (2011) CYP24A1 mutations in idiopathic infantile hypercalcemia. N Engl J Med 365(18):1741–1743CrossRefPubMed
4.
Zurück zum Zitat Dauber A, Nguyen TT, Sochett E et al (2012) Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab 97(2):E268–E274CrossRefPubMed Dauber A, Nguyen TT, Sochett E et al (2012) Genetic defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a patient with severe infantile hypercalcemia. J Clin Endocrinol Metab 97(2):E268–E274CrossRefPubMed
5.
Zurück zum Zitat Castanet M, Mallet E, Kottler M-L (2013) Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin D supplement recommendations. J Pediatr 163(4):1208–1210CrossRefPubMed Castanet M, Mallet E, Kottler M-L (2013) Lightwood syndrome revisited with a novel mutation in CYP24 and vitamin D supplement recommendations. J Pediatr 163(4):1208–1210CrossRefPubMed
6.
Zurück zum Zitat Meusburger E, Mündlein A, Zitt E, Obermayer-Pietsch B, Kotzot D, Lhotta K (2013) Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcaemia and a novel CYP24A1 mutation. Clin Kidney J 6(2):211–215CrossRefPubMedPubMedCentral Meusburger E, Mündlein A, Zitt E, Obermayer-Pietsch B, Kotzot D, Lhotta K (2013) Medullary nephrocalcinosis in an adult patient with idiopathic infantile hypercalcaemia and a novel CYP24A1 mutation. Clin Kidney J 6(2):211–215CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Fencl F, Bláhová K, Schlingmann KP, Konrad M, Seeman T (2013) Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr 172(1):45–49CrossRefPubMed Fencl F, Bláhová K, Schlingmann KP, Konrad M, Seeman T (2013) Severe hypercalcemic crisis in an infant with idiopathic infantile hypercalcemia caused by mutation in CYP24A1 gene. Eur J Pediatr 172(1):45–49CrossRefPubMed
8.
Zurück zum Zitat Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ (2013) Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 190(2):552–557CrossRefPubMed Dinour D, Beckerman P, Ganon L, Tordjman K, Eisenstein Z, Holtzman EJ (2013) Loss-of-function mutations of CYP24A1, the vitamin D 24-hydroxylase gene, cause long-standing hypercalciuric nephrolithiasis and nephrocalcinosis. J Urol 190(2):552–557CrossRefPubMed
9.
Zurück zum Zitat Nesterova G, Malicdan MC, Yasuda K et al (2013) 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol CJASN 8(4):649–657CrossRefPubMed Nesterova G, Malicdan MC, Yasuda K et al (2013) 1,25-(OH)2D-24 hydroxylase (CYP24A1) deficiency as a cause of nephrolithiasis. Clin J Am Soc Nephrol CJASN 8(4):649–657CrossRefPubMed
10.
Zurück zum Zitat Colussi G, Ganon L, Penco S et al (2014) Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc 29(3):636–643 Colussi G, Ganon L, Penco S et al (2014) Chronic hypercalcaemia from inactivating mutations of vitamin D 24-hydroxylase (CYP24A1): implications for mineral metabolism changes in chronic renal failure. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc—Eur Ren Assoc 29(3):636–643
11.
Zurück zum Zitat Jacobs TP, Kaufman M, Jones G et al (2014) A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab 99(3):708–712CrossRefPubMedPubMedCentral Jacobs TP, Kaufman M, Jones G et al (2014) A lifetime of hypercalcemia and hypercalciuria, finally explained. J Clin Endocrinol Metab 99(3):708–712CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Wolf P, Müller-Sacherer T, Baumgartner-Parzer S et al (2014) A case of “late-onset” idiopathic infantile hypercalcemia secondary to mutations in the CYP24A1 gene. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 20(5):e91–e95 Wolf P, Müller-Sacherer T, Baumgartner-Parzer S et al (2014) A case of “late-onset” idiopathic infantile hypercalcemia secondary to mutations in the CYP24A1 gene. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 20(5):e91–e95
13.
Zurück zum Zitat Dowen FE, Sayers JA, Hynes AM, Sayer JA (2014) CYP24A1 mutation leading to nephrocalcinosis. Kidney Int 85(6):1475CrossRefPubMed Dowen FE, Sayers JA, Hynes AM, Sayer JA (2014) CYP24A1 mutation leading to nephrocalcinosis. Kidney Int 85(6):1475CrossRefPubMed
14.
Zurück zum Zitat Figueres M-L, Linglart A, Bienaime F et al (2015) Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am J Kidney Dis Off J Natl Kidney Found 65(1):122–126CrossRef Figueres M-L, Linglart A, Bienaime F et al (2015) Kidney function and influence of sunlight exposure in patients with impaired 24-hydroxylation of vitamin D due to CYP24A1 mutations. Am J Kidney Dis Off J Natl Kidney Found 65(1):122–126CrossRef
15.
Zurück zum Zitat Molin A, Baudoin R, Kaufmann M et al (2015) CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J Clin Endocrinol Metab 100(10):E1343–E1352CrossRefPubMed Molin A, Baudoin R, Kaufmann M et al (2015) CYP24A1 mutations in a cohort of hypercalcemic patients: evidence for a recessive trait. J Clin Endocrinol Metab 100(10):E1343–E1352CrossRefPubMed
16.
Zurück zum Zitat Cools M, Goemaere S, Baetens D et al (2015) Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study. Bone 81:89–96CrossRefPubMed Cools M, Goemaere S, Baetens D et al (2015) Calcium and bone homeostasis in heterozygous carriers of CYP24A1 mutations: a cross-sectional study. Bone 81:89–96CrossRefPubMed
17.
Zurück zum Zitat Ketha H, Kumar R, Singh RJ (2016) LC-MS/MS for identifying patients with CYP24A1 mutations. Clin Chem 62(1):236–242CrossRefPubMed Ketha H, Kumar R, Singh RJ (2016) LC-MS/MS for identifying patients with CYP24A1 mutations. Clin Chem 62(1):236–242CrossRefPubMed
18.
Zurück zum Zitat O’Keeffe DT, Tebben PJ, Kumar R, Singh RJ, Wu Y, Wermers RA (2016) Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect. Osteoporos Int 1–15. doi:10.1007/s00198-016-3615-6 O’Keeffe DT, Tebben PJ, Kumar R, Singh RJ, Wu Y, Wermers RA (2016) Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect. Osteoporos Int 1–15. doi:10.​1007/​s00198-016-3615-6
19.
Zurück zum Zitat Gigante M, Santangelo L, Diella S et al (2016) Mutational spectrum of CYP24A1 gene in a cohort of Italian patients with idiopathic infantile hypercalcemia. Nephron 133(3):193–204CrossRefPubMed Gigante M, Santangelo L, Diella S et al (2016) Mutational spectrum of CYP24A1 gene in a cohort of Italian patients with idiopathic infantile hypercalcemia. Nephron 133(3):193–204CrossRefPubMed
20.
Zurück zum Zitat Halbritter J, Baum M, Hynes AM et al (2015) Fourteen monogenic genes account for 15 % of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551CrossRefPubMed Halbritter J, Baum M, Hynes AM et al (2015) Fourteen monogenic genes account for 15 % of nephrolithiasis/nephrocalcinosis. J Am Soc Nephrol 26(3):543–551CrossRefPubMed
21.
Zurück zum Zitat St-Arnaud R, Arabian A, Travers R et al (2000) Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141(7):2658–2666CrossRefPubMed St-Arnaud R, Arabian A, Travers R et al (2000) Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 141(7):2658–2666CrossRefPubMed
Metadaten
Titel
A novel CYP24A1 genotype associated to a clinical picture of hypercalcemia, nephrolithiasis and low bone mass
verfasst von
Pietro Manuel Ferraro
Angelo Minucci
Aniello Primiano
Elisa De Paolis
Jacopo Gervasoni
Silvia Persichilli
Alessandro Naticchia
Ettore Capoluongo
Giovanni Gambaro
Publikationsdatum
17.09.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Urolithiasis / Ausgabe 3/2017
Print ISSN: 2194-7228
Elektronische ISSN: 2194-7236
DOI
https://doi.org/10.1007/s00240-016-0923-4

Weitere Artikel der Ausgabe 3/2017

Urolithiasis 3/2017 Zur Ausgabe

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.